

Rona Yaeger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5857387/publications.pdf>

Version: 2024-02-01

80
papers

16,651
citations

71061

41
h-index

60583

81
g-index

82
all docs

82
docs citations

82
times ranked

23175
citing authors

#	ARTICLE	IF	CITATIONS
1	Survival After Induction Chemotherapy and Chemoradiation Versus Chemoradiation and Adjuvant Chemotherapy for Locally Advanced Rectal Cancer. <i>Oncologist</i> , 2022, 27, 380-388.	1.9	12
2	Simplified Graded Infusion Strategy for Mitigation of Oxaliplatin Hypersensitivity. <i>Clinical Colorectal Cancer</i> , 2022, , .	1.0	2
3	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. <i>Cell</i> , 2022, 185, 563-575.e11.	13.5	223
4	Same-Cell Co-Occurrence of RAS Hotspot and BRAF V600E Mutations in Treatment-Naive Colorectal Cancer. <i>JCO Precision Oncology</i> , 2022, 6, e2100365.	1.5	1
5	Immune biomarkers and response to checkpoint inhibition of BRAFV600 and BRAF non-V600 altered lung cancers. <i>British Journal of Cancer</i> , 2022, 126, 889-898.	2.9	8
6	Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy. <i>Journal of Clinical Oncology</i> , 2022, 40, 2546-2556.	0.8	292
7	Different hotspot p53 mutants exert distinct phenotypes and predict outcome of colorectal cancer patients. <i>Nature Communications</i> , 2022, 13, 2800.	5.8	21
8	<i>BRAF</i> -Mutated Advanced Colorectal Cancer: A Rapidly Changing Therapeutic Landscape. <i>Journal of Clinical Oncology</i> , 2022, 40, 2706-2715.	0.8	21
9	PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 2363-2376.	13.9	588
10	Characterization and Clinical Outcomes of DNA Mismatch Repair-deficient Small Bowel Adenocarcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 1429-1437.	3.2	23
11	Chromothripsis drives the evolution of gene amplification in cancer. <i>Nature</i> , 2021, 591, 137-141.	13.7	228
12	Primary Tumor Location and Outcomes After Cytoreductive Surgery and Intraperitoneal Chemotherapy for Peritoneal Metastases of Colorectal Origin. <i>Annals of Surgical Oncology</i> , 2021, 28, 1109-1117.	0.7	5
13	Tumor Mutational Burden and Mismatch Repair Deficiency Discordance as a Mechanism of Immunotherapy Resistance. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 130-133.	2.3	14
14	<i>KRAS</i> G12C Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 2604-2612.	3.2	20
15	Clinical Calculator Based on Molecular and Clinicopathologic Characteristics Predicts Recurrence Following Resection of Stage I-III Colon Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 911-919.	0.8	34
16	<i>EGFR</i> Amplification in Metastatic Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1561-1569.	3.0	12
17	Tumor-Infiltrating Lymphocytes, Tumor Mutational Burden, and Genetic Alterations in Microsatellite Unstable, Microsatellite Stable, or Mutant <i>POLE/POLD1</i> Colon Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 817-826.	1.5	18
18	Overall survival (OS) with encorafenib (enco) + cetuximab (cetux) in BEACON CRC: Effect of prior therapy for BRAF V600E-mutant metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 3583-3583.	0.8	3

#	ARTICLE	IF	CITATIONS
19	Type of recurrence is associated with disease-free survival after salvage surgery for locally recurrent rectal cancer. <i>International Journal of Colorectal Disease</i> , 2021, 36, 2603-2611.	1.0	7
20	A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1683-1692.	3.0	66
21	Early TP53 Alterations Shape Gastric and Esophageal Cancer Development. <i>Cancers</i> , 2021, 13, 5915.	1.7	7
22	Development and Assessment of a Clinical Calculator for Estimating the Likelihood of Recurrence and Survival Among Patients With Locally Advanced Rectal Cancer Treated With Chemotherapy, Radiotherapy, and Surgery. <i>JAMA Network Open</i> , 2021, 4, e2133457.	2.8	16
23	Is Hepatectomy Justified for BRAF Mutant Colorectal Liver Metastases?. <i>Annals of Surgery</i> , 2020, 271, 147-154.	2.1	82
24	Retained mismatch repair protein expression occurs in approximately 6% of microsatellite instability-high cancers and is associated with missense mutations in mismatch repair genes. <i>Modern Pathology</i> , 2020, 33, 871-879.	2.9	58
25	Discordant DNA mismatch repair protein status between synchronous or metachronous gastrointestinal carcinomas: frequency, patterns, and molecular etiologies. <i>Familial Cancer</i> , 2020, 20, 201-213.	0.9	8
26	Quantitative assessment of tumor-infiltrating lymphocytes in mismatch repair proficient colon cancer. <i>Oncolmmunology</i> , 2020, 9, 1841948.	2.1	3
27	Heat Shock Factor 1-dependent extracellular matrix remodeling mediates the transition from chronic intestinal inflammation to colon cancer. <i>Nature Communications</i> , 2020, 11, 6245.	5.8	51
28	Specific Mutations in APC, but Not Alterations in DNA Damage Response, Associate With Outcomes of Patients With Metastatic Colorectal Cancer. <i>Gastroenterology</i> , 2020, 159, 1975-1978.e4.	0.6	26
29	EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer. <i>Cancer Discovery</i> , 2020, 10, 1129-1139.	7.7	245
30	Lineage Reversion Drives WNT Independence in Intestinal Cancer. <i>Cancer Discovery</i> , 2020, 10, 1590-1609.	7.7	52
31	Mismatch Repair-Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 3271-3279.	3.2	118
32	ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 757-770.	12.5	218
33	Coaltered <i>Ras/B-raf</i> and <i>TP53</i> Is Associated with Extremes of Survivorship and Distinct Patterns of Metastasis in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1077-1085.	3.2	62
34	Overcoming Adaptive Resistance to KRAS Inhibitors Through Vertical Pathway Targeting. <i>Clinical Cancer Research</i> , 2020, 26, 1538-1540.	3.2	25
35	Resistance to TRK inhibition mediated by convergent MAPK pathway activation. <i>Nature Medicine</i> , 2019, 25, 1422-1427.	15.2	144
36	Genomic stratification beyond <i>Ras/B-Raf</i> in colorectal liver metastasis patients treated with hepatic arterial infusion. <i>Cancer Medicine</i> , 2019, 8, 6538-6548.	1.3	8

#	ARTICLE	IF	CITATIONS
37	Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E-Mutated Colorectal Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 1632-1643.	13.9	918
38	A rectal cancer organoid platform to study individual responses to chemoradiation. <i>Nature Medicine</i> , 2019, 25, 1607-1614.	15.2	320
39	Contemporary Validation of a Nomogram Predicting Colon Cancer Recurrence, Revealing All-Stage Improved Outcomes. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz015.	1.4	16
40	V211D Mutation in MEK1 Causes Resistance to MEK Inhibitors in Colon Cancer. <i>Cancer Discovery</i> , 2019, 9, 1182-1191.	7.7	27
41	Rare BRAF mutations in pancreatic neuroendocrine tumors may predict response to RAF and MEK inhibition. <i>PLoS ONE</i> , 2019, 14, e0217399.	1.1	12
42	TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma. <i>Cancer Discovery</i> , 2019, 9, 1064-1079.	7.7	254
43	Genetics of rectal cancer and novel therapies: primer for radiologists. <i>Abdominal Radiology</i> , 2019, 44, 3743-3750.	1.0	10
44	Majority of <i>B2M</i> -Mutant and -Deficient Colorectal Carcinomas Achieve Clinical Benefit From Immune Checkpoint Inhibitor Therapy and Are Microsatellite Instability-High. <i>JCO Precision Oncology</i> , 2019, 3, 1-14.	1.5	61
45	Response to Anti-EGFR Therapy in Patients with BRAF non-V600E-Mutant Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 7089-7097.	3.2	79
46	SMAD4 Loss in Colorectal Cancer Patients Correlates with Recurrence, Loss of Immune Infiltrate, and Chemoresistance. <i>Clinical Cancer Research</i> , 2019, 25, 1948-1956.	3.2	71
47	RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling. <i>Nature Medicine</i> , 2019, 25, 284-291.	15.2	125
48	Assessment of a Watch-and-Wait Strategy for Rectal Cancer in Patients With a Complete Response After Neoadjuvant Therapy. <i>JAMA Oncology</i> , 2019, 5, e185896.	3.4	347
49	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. <i>Nature Genetics</i> , 2019, 51, 202-206.	9.4	2,702
50	Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions. <i>Cancer Research</i> , 2019, 79, 1047-1053.	0.4	112
51	FOLFICIS Treatment and Genomic Correlates of Response in Advanced Anal Squamous Cell Cancer. <i>Clinical Colorectal Cancer</i> , 2019, 18, e39-e52.	1.0	21
52	Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties. <i>Cancer Discovery</i> , 2018, 8, 648-661.	7.7	97
53	Combined BRAF, EGFR, and MEK Inhibition in Patients with <i>BRAF</i> V600E-Mutant Colorectal Cancer. <i>Cancer Discovery</i> , 2018, 8, 428-443.	7.7	448
54	Association of Preoperative and Postoperative Serum Carcinoembryonic Antigen and Colon Cancer Outcome. <i>JAMA Oncology</i> , 2018, 4, 309.	3.4	146

#	ARTICLE	IF	CITATIONS
55	Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer. <i>Cancer Cell</i> , 2018, 33, 125-136.e3.	7.7	589
56	Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer. <i>JAMA Oncology</i> , 2018, 4, e180071.	3.4	404
57	Balancing RAF, MEK, and EGFR Inhibitor Doses to Achieve Clinical Responses and Modulate Toxicity in <i>BRAF</i> V600E Colorectal Cancer. <i>JCO Precision Oncology</i> , 2018, 2018, 1-4.	1.5	5
58	Colorectal cancer genomics and designing rational trials. <i>Annals of Translational Medicine</i> , 2018, 6, 159-159.	0.7	19
59	Chromosome 20q Amplification Defines a Subtype of Microsatellite Stable, Left-Sided Colon Cancers with Wild-type RAS/RAF and Better Overall Survival. <i>Molecular Cancer Research</i> , 2017, 15, 708-713.	1.5	24
60	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. <i>Nature Medicine</i> , 2017, 23, 703-713.	15.2	2,473
61	Clinical Features and Outcomes of Patients with Colorectal Cancers Harboring NRAS Mutations. <i>Clinical Cancer Research</i> , 2017, 23, 4753-4760.	3.2	56
62	Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition. <i>Cancer Research</i> , 2017, 77, 6513-6523.	0.4	58
63	Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy. <i>Ophthalmology</i> , 2017, 124, 1788-1798.	2.5	95
64	Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. <i>Nature</i> , 2017, 548, 234-238.	13.7	394
65	Clinical and genetic determinants of ovarian metastases from colorectal cancer. <i>Cancer</i> , 2017, 123, 1134-1143.	2.0	43
66	OncoKB: A Precision Oncology Knowledge Base. <i>JCO Precision Oncology</i> , 2017, 2017, 1-16.	1.5	1,266
67	Systemic Therapy for Metastatic Colorectal Cancer: From Current Standards to Future Molecular Targeted Approaches. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 246-256.	1.8	20
68	PI3K pathway mutations are associated with longer time to local progression after radioembolization of colorectal liver metastases. <i>Oncotarget</i> , 2017, 8, 23529-23538.	0.8	31
69	Recurrent, truncating <i>SOX9</i> mutations are associated with <i>SOX9</i> overexpression, <i>KRAS</i> mutation, and <i>TP53</i> wild type status in colorectal carcinoma. <i>Oncotarget</i> , 2016, 7, 50875-50882.	0.8	26
70	Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels. <i>Journal of Clinical Oncology</i> , 2016, 34, 2141-2147.	0.8	204
71	Genomic Alterations Observed in Colitis-Associated Cancers Are Distinct From Those Found in Sporadic Colorectal Cancers and Vary by Type of Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2016, 151, 278-287.e6.	0.6	147
72	Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF. <i>Molecular Cancer Research</i> , 2016, 14, 296-301.	1.5	46

#	ARTICLE	IF	CITATIONS
73	RAF plus EGFR Inhibition for BRAF-Mutant Metastatic Colorectal Cancer—Response. <i>Clinical Cancer Research</i> , 2015, 21, 2188-2188.	3.2	3
74	RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer. <i>Cancer</i> , 2015, 121, 1195-1203.	2.0	146
75	Pilot Trial of Combined BRAF and EGFR Inhibition in <i>BRAF</i> -Mutant Metastatic Colorectal Cancer Patients. <i>Clinical Cancer Research</i> , 2015, 21, 1313-1320.	3.2	240
76	Axillary Lymph Node Involvement, a Unique Pattern of Metastasis in <i>BRAF</i> -Mutant Colorectal Cancer. <i>JAMA Oncology</i> , 2015, 1, 686.	3.4	8
77	AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants. <i>Molecular Cancer Research</i> , 2015, 13, 1003-1008.	1.5	20
78	Impact of somatic mutations on patterns of metastasis in colorectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2015, 6, 645-9.	0.6	66
79	BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. <i>Cancer</i> , 2014, 120, 2316-2324.	2.0	170
80	Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. <i>Nature</i> , 2012, 486, 532-536.	13.7	1,605